Linical (2183) Q3 2026 earnings summary

Executive summary

• Net sales for the nine months ended December 31, 2025, were ¥6,837 million, down 14.0% year-over-year, with increases in Japan, Europe, Taiwan, and China, but declines in the US and South Korea.

• Operating loss increased on a consolidated basis, mainly from significant losses in the US and Europe, despite improvements in Japan, Taiwan, and China.

• Ordinary loss increased to ¥1,233 million from ¥261 million loss year-over-year.

• Net loss attributable to owners of parent was ¥1,551 million, compared to a profit of ¥1,551 million in the previous period.

• Comprehensive loss for the period was ¥1,222 million, compared to ¥217 million loss year-over-year.

Financial highlights

• Gross profit declined to ¥1,111 million from ¥1,858 million year-over-year.

• Selling, general and administrative expenses increased to ¥2,388 million from ¥2,190 million.

• Net income per share was negative ¥68.68, compared to negative ¥14.03 in the prior year.

• Total assets decreased to ¥13,994 million as of December 31, 2025, from ¥16,775 million as of March 31, 2025.

• Shareholders' equity ratio declined to 40.5% from 43.2% at the previous fiscal year-end.

Outlook and guidance

• Full-year forecast for FY ending March 2026 projects net sales of ¥10,437 million, up 10.4% year-over-year.

• Operating profit forecasted at ¥1,350 million, up 14.4% year-over-year.

• Ordinary profit expected to reach ¥1,400 million, up 15.0% year-over-year.

• Net profit projected at ¥1,700 million, up 18.2% year-over-year, with EPS of ¥75.27.

• Dividend per share maintained at ¥16.00.